Emerging Company Profile
With $50M A round led by Versant, Westlake, newco Capsida aims to target AAV vectors to specific tissues
Emerging Company Profile: Thousand Oaks, Calif.-based biotech is engineering AAV vectors to target specific tissues while avoiding the liver
With a $50 million series A led by Versant and Westlake, Thousand Oaks, Calif.-based Capsida is engineering AAV vectors to target specific tissues while avoiding the liver.
Capsida emerged from stealth on Thursday to tackle one of the biggest challenges holding AAV gene therapy back from becoming a mainstream modality — selective tissue targeting outside the liver.